...concerns that we have…how do you define what shows promise? Through the accelerated approval pathway, you’re not necessarily showing the endpoint of a cure or ultimate survival."
— Sergio Santiviago, AHIP’s vice president for drug policy,
spoke with AIS’s Radar on Drug Benefits about why concerns are mounting about
the FDA’s accelerated approval process, from the burden carried by
public-sector plans to whether these drugs offer the best patient outcomes.
No comments:
Post a Comment